Haemopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B

Acta Haematologica

Volumn 113, Issue 2, 2005, Pages 104-108

  Krüger, William H ^a,b   Rüssmann, Bettina ^a   De Wit, Maike ^a   Kröger, Nicolaus ^a   Renges, Helmut ^a   Sobottka, Ingo ^a   Zander, Axel R ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Allogeneic stem cell transplantation; Aspergillosis; Candidosis; Immunosuppression

Indexed keywords

ACICLOVIR; AMPHOTERICIN B LIPID COMPLEX; BETA LACTAM ANTIBIOTIC; BUSULFAN; CEFTAZIDIME; COTRIMOXAZOLE; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; ITRACONAZOLE; METHOTREXATE; PENTAMIDINE ISETHIONATE; PYRROLE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; THYMOCYTE ANTIBODY; VANCOMYCIN; AMPHOTERICIN B; ANTIFUNGAL AGENT; CYCLOSPORIN; LIPOSOME;

ADOLESCENT; ADULT; AGED; ANAMNESIS; ANTIBIOTIC PROPHYLAXIS; ARTICLE; ASPERGILLOSIS; BACTERIAL INFECTION; BRONCHITIS; CAUSE OF DEATH; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; FEMALE; FUNGUS; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITAL DISCHARGE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; MALE; MASTOIDITIS; MORTALITY; MYCOSIS; MYELOABLATIVE CONDITIONING; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; PROBABILITY; REINFECTION; SECONDARY PREVENTION; SEPTICEMIA; SIDE EFFECT; SYSTEMIC DISEASE; TREATMENT WITHDRAWAL; DRUG EFFECT; GRAFT SURVIVAL; HEMATOLOGIC DISEASE; INFANT; MIDDLE AGED; PRESCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; FEMALE; GRAFT SURVIVAL; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LIPOSOMES; MALE; MIDDLE AGED; MYCOSES; OPPORTUNISTIC INFECTIONS;

EID: 17144431416     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083447     Document Type: Article

References (19)

1. Offner F, Cordonnier C, Ljungman P, Prentice HG, Engelhard D, De Bacquer D, Meunier F, de Pauw B: Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 1998;26:1098-1103.
2. Denning DW: Invasive aspergillosis. Clin Infect Dis 1998;26:781-803.
3. Latge JP: Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 1999;12:310-350.
4. Ribaud P, Chastang C, Latge JP, Baffroy-Lafitte L, Parquet N, Devergie A, Esperou H, Selimi F, Rocha V, Esperou H, Selimi F, Rocha V, Derouin F, Socie G, Gluckman E: Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 1999;28:322-330.
5. Marr KA, Carter RA, Crippa F, Wald A, Corey L: Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909-917.
6. Zander AR, Berger C, Kröger N, Stockschlader M, Krüger W, Horstmann M, Grimm J, Zeller W, Kabisch H, Erttmann R, Schönrock P, Kuse R, Braumann D, Illiger HJ, Fiedler W, de Wit M, Hossfeld KD, Weh HJ: High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission. Clin Cancer Res 1997;3:2671-2675.
7. Kröger N, Krüger W, Wacker-Backhaus G, Hegewisch-Becker S, Stockschläder M, Fuchs N, Rüssmann B, Renges H, Dürken M, Bielack S, de Wit M, Schuch G, Bartels H, Braumann D, Kuse R, Kabisch H, Erttmann R, Zander AR: Intensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 1998;22:1029-1033.
8. Kröger N, Schetelig J, Zabelina T, Krüger W, Renges H, Stute N, Schrum J, Kabisch H, Siegert W, Zander AR: A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. Bone Marrow Transplant 2001;28:643-647.
9. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ: Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002;34/1:7-14.
10. Krüger W, Rüssmann B, Kröger N, Salomon C, Ekopf N, Elsner HA, Kaulfers PM, Mack D, Fuchs N, Dürken M, Kabisch H, Erttmann R, Zander AR: Early infections in patients undergoing bone marrow or blood stem cell transplantation - A 7 year single centre investigation of 409 cases. Bone Marrow Transplant 1999;23:589-597.
11. Cordonnier C, Beaune J, Offner F, Marinus A, Ljungman P, Meunier F: Aspergillosis prior to bone marrow transplantation. Infectious Diseases Working Party of the EBMT and the EORTC Invasive Fungal Infections Cooperative Group (letter). Bone Marrow Transplant 1995;16:323-324.
12. Hoover M, Morgan ER, Kletzel M: Prior fungal infection is not a contraindication to bone marrow transplant in patients with acute leukemia. Med Pediatr Oncol 1997;28/4:268-273.
13. Martino R, Nomdedeu J, Altes A, Sureda A, Brunet S, Martinez C, Domingo-Albos A: Successful bone marrow transplantation in patients with previous invasive fungal infections: Report of four cases. Bone Marrow Transplant 1994;13/3:265-269.
14. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R: Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991;325:1274-1277.
15. Carreras E, Batlle M, Redondo M, Esteve J, Ros S, Rovira M, Sierra J, Urbano-Ispizua A, Marin P, Merino A: Intravenous amphotericin B as prevention of deep mycoses in allogeneic bone marrow transplantation. Med Clin (Barc) 1994;103:761-765.
16. Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL, Leitz GJ, Territo MC: Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003;138:705-713.
17. Kaptan K, Ural AU, Cetin T, Aveu F, Beyan C, Yalcin A: Itraconazole is not effective for the prophylaxis of fungal infections in patients with neutropenia. J Infect Chemother 2003;9/1:40-45.
18. Keating GM, Jarvis B: Caspofungin. Drugs 2001;61:1121-1129.
19. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-415.